CULLINAN ONCOLOGY INC

Cullinan Oncology is a clinical-stage biopharmaceutical company whose core business model involves developing cancer therapies through preclinical and clinical research that requires animal testing. The company’s pipeline, including candidates like CLN-617 in Phase 1 trials for solid tumors, is advanced through standard biomedical research protocols that rely on animal models to assess safety and efficacy before human trials. As a biotechnology firm engaged in drug development, Cullinan’s operations are inherently tied to the commercial exploitation of animals in laboratory research, a practice categorized under the animal_exploitation exclusion.

The evidence gathered from public filings and third-party screens, including flagging by Cruelty Free Investors, indicates the company’s involvement in animal-based research, though specific details on the scale, species, or protocols were not provided in the sourced materials. This lack of detailed public disclosure is typical for early-stage biotech firms but confirms the company’s reliance on animal testing as a standard component of its therapeutic development process. Without a publicly available animal welfare policy or commitment to alternative methods, the company’s operations fall under the broad animal_exploitation criteria.